Renal Cell Carcinoma Clinical Roundup

News Articles

City of Hope, TGen Researchers Find Link Between Gut Microbiome And Cancer Treatment Outcomes

(City of Hope) Aug 19, 2020 - Greater gut microbial diversity in patients with metastatic kidney cancer is associated with better treatment outcomes on FDA-approved immunotherapy regimens, based on a study published today in the journal European Urology.

Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

(Yahoo! News) Aug 18, 2020 - Arrowhead Pharmaceuticals Inc. today announced that it has dosed the first patient in AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).

Immunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer

(Yahoo! Finance) Aug 18, 2020 - Median Overall Survival (OS) was reached at 25 months in the control group treated with sunitinib, while the final median OS value in the ilixadencel treatment group has not yet been reached, indicating a survival benefit in the study’s co-primary endpoint.

Diabetes Linked to Increased Kidney Cancer Risk, But Only in Slim

(Medscape Medical News) Aug 13, 2020 - Postmenopausal women with BMIs under 30 are paradoxically more likely to develop kidney cancer than the women of the same age with higher BMIs and larger waists.

View all renal cell carcinomca (rcc) cancer news

Publications

Angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment in patients with advanced renal cell carcinoma

(Clinical cancer research : an official journal of the American Association for Cancer Research) - 2020-08-21

First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

(International journal of cancer) - 2020-08-02

Regulatory Considerations for Contribution of Effect of Drugs used in Combination Regimens: Renal Cell Cancer Case Studies

(Clinical cancer research : an official journal of the American Association for Cancer Research) - 2020-08-01

OBR Green

Metastatic Renal Cell Carcinoma: Combining and Sequencing Novel Agents

August 2020

At the ASCO20 Virtual Education Program, Jaleh Fallah, MD, a Hematology/Oncology Fellow at the Cleveland Clinic, reviewed the outcomes of single-agent immunotherapy and immunotherapy-based combinations in the front-line renal cell carcinoma setting and discussed the choice of treatment following disease progression.